Recent Updates
Recently added Catalysts

GSK investigational vaccine 2186877A

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Sep 21, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment370
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00992784Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly PeoplePHASE3 COMPLETED 370Oct 15, 2009May 27, 2010Sep 21, 201824 Germany, Netherlands +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Day 0-6

Grade 3 ecchymosis, redness and swelling was ≥ 100 millimeter (mm) and grade 3 pain was considerable pain at rest, that prevented normal everyday activities.

Duration of Solicited Local AEs
Day 0-6

Duration was defined as number of days with any grade of local symptoms.

Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Day 0-6

Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C-≤ 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade, grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.

Duration of Solicited General AEs
Day 0-6

Duration was defined as number of days with any grade of general symptoms.

Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Day 0-20

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit
Day 0-179

For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting AEs of Specific Interest (AESI)
Day 0-179

AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) up to Day 180
Up to Day 180

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) After Day 180
After Day 180

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.

Secondary Endpoints
Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21
Day 0 and Day 21
HI Antibody Titers at Day 180
Day 180
The Number of Subjects Seropositive to HI Antibodies at Days 0 and 21
Day 0 and Day 21
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
New generation influenza vaccine GSK2186877A GroupEXPERIMENTALSubjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
Fluarix elderly GroupACTIVE_COMPARATORSubjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
Fluarix young GroupACTIVE_COMPARATORSubjects aged 19-43 years receiving 1 dose of Fluarix vaccine
Interventions
NameTypeDescription
GSK investigational vaccine 2186877ABIOLOGICALSingle dose, intramuscular injection
FluarixTMBIOLOGICALSingle dose, intramuscular injection
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites24

Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of s...

Countries:GermanyNetherlandsSweden
Unlock Eligibility Criteria